{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"30","value":"27"}]}],"title":"Baseline Score"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22","upperLimit":"30","value":"28"}]}],"title":"4 month Score"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1","upperLimit":"18","value":"1"}]}],"title":"Change from Baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Neurologic functioning will be assessed using the Mini-Mental Status Evaluation (MMSE), a standardized, bedside tool for evaluation of higher mental function. This assessment is based on a 30-point scale (0-30) with higher scores associated with better performance.","dispersionType":"Full Range","groups":[{"description":"Induction Cycles 1-3: Methotrexate 8gm/m\\^2 days 1 \\& 15; Leucovorin 100 mg/m\\^2 days 2 \\& 16; Rituximab 375 mg/m\\^2 days 3, 10, 17 \\& 24 of cycle 1, days 3 \\& 10 of cycle 2; Temozolomide 150 mg/m\\^2/day PO days 7-11\n\nInduction Cycle 4: Temozolomide 150 mg/m\\^2/day PO days 7-11; Methotrexate 8gm/m\\^2 day 15; Leucovorin 100 mg/m\\^2 day 16\n\nConsolidation Cycle 5: Methotrexate 8gm/m\\^2 days 1; Leucovorin 100 mg/m\\^2 days 2; Temozolomide 150 mg/m\\^2/day PO days 7-11\n\nConsolidation Cycle 6: Cytarabine 2 g/m\\^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m\\^2/day starting day 14 until ANC recovers (\\>= 500 for 2 consecutive days or \\>= 1500 for one day)","id":"OG000","title":"Intensive Combination Chemo & Immunotherapy"}],"paramType":"MEDIAN","populationDescription":"Only 14 participants had both baseline and 4 month MMSE evaluations reported.","reportingStatus":"POSTED","timeFrame":"Baseline & month 4","title":"Change From Baseline in Mini-Mental Status Evaluation at 4 Months","type":"SECONDARY","unitOfMeasure":"units on a scale"}